A carregar...
The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis
BACKGROUND: Recently, several high-quality clinical randomized controlled trials (RCTs) have identified that cyclin-dependent kinases (CDKs) 4/6 inhibitors obtained a great safety and efficacy, which can be consequently applied as a combination therapy with letrozole or fulvestrant for women who had...
Na minha lista:
| Publicado no: | Medicine (Baltimore) |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wolters Kluwer Health
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5976281/ https://ncbi.nlm.nih.gov/pubmed/29768351 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000010746 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|